Transverse Myelitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with an acute (sudden/active) episode of a condition called Neuromyelitis Optica Spectrum Disorder (NMOSD).
- You are between 18 and 65 years old (any gender is welcome).
- A blood test has shown you carry a specific marker called AQP4-IgG, detected using a particular testing method called the cell-based assay (CBA).
- You (or your legal representative) are able to understand what the study involves, are willing to follow the study's rules, and can sign a consent form agreeing to take part.
Who may not be able to join:
- You are currently pregnant or breastfeeding.
- Doctors are unable to insert an IV line into your veins, or you have had an allergic reaction to a blood-filtering treatment called plasmapheresis in the past.
- You have a medical reason why you cannot receive high-dose steroid treatment given through a drip (intravenous methylprednisolone).
- You have used certain types of targeted antibody treatments (monoclonal antibodies) in the last 6 months, or a specific type of medication called FcRn antagonists in the last 3 months.
- You need to take a type of blood pressure medication called ACE inhibitors within one week before or during the study, and are unable to stop taking them.
- You have serious bleeding problems or a bleeding disorder.
- You have severe heart failure.
- You have a severe infection.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8615899968330
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the effectiveness of the treatment, the change in the Kurtzke Expanded Disability Status Scale (EDSS) score is evaluated one month after the start of treatment compared to the baseline. The baseline is defined as the patient's condition before
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.